John H. Beigel, MD

The National Institute of Allergy and Infectious Diseases, National Institutes of Health

Disclosure(s): No financial relationships to disclose

Poster(s):

• 1149 - Resistance Analyses of Patient Viral Samples from the Remdesivir Phase 3 Adaptive COVID-19 Treatment Trial-1 (ACTT-1)
  Friday, October 21, 2022

  12:15 PM – 1:30 PM US ET